LWAC
BMRN icon

Laurel Wealth Advisors (California)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Laurel Wealth Advisors (California)’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,955
Closed -$228K – 664
2022
Q1 		$228K Buy
+2,955
New +$247K 0.02% 679

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Laurel Wealth Advisors (California)'s BMRN Position: Q2 2022 in Review

Laurel Wealth Advisors (California) sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2022, closing a stake of 2,955 shares — an estimated $228K sold.

Laurel Wealth Advisors (California) first reported a position in BMRN in Q1 2022 and held it in 1 quarter. The position peaked at $228K in Q1 2022. 542 funds tracked by Wall St. Rank hold BMRN as of Q2 2022.

  • Laurel Wealth Advisors (California) reported no remaining BioMarin Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Laurel Wealth Advisors (California) sold 2,955 BioMarin Pharmaceuticals shares in Q2 2022, an estimated $228K.
  • Laurel Wealth Advisors (California) first reported a position in BioMarin Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Laurel Wealth Advisors (California)'s BioMarin Pharmaceuticals position peaked at $228K in Q1 2022.
  • 542 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2022.

Based on Laurel Wealth Advisors (California)'s 13F filing for Q2 2022, filed 12 Aug 2022.